Literature DB >> 25813091

The emerging role of miRNAs in combined cancer therapy.

Hong W Yu1, William C Cho.   

Abstract

MicroRNAs (miRNAs) control physiological and fundamental processes in cellular development and differentiation by modulating the expression of their target genes. They have been found to participate in cell transformation and multiplication by functioning as oncomiRs and tumor suppressors in diverse cancers. Introduction of antisense miRNAs (antagomiRs) into primary cells such as immune cells by lipofection, viral vectors or electroporation can achieve the specific silencing of individual miRNAs. Therefore, harnessing miRNAs may lead to promising cancer therapeutics. There is emerging evidence demonstrating the involvement of miRNAs in combined cancer therapies, including chemotherapy, radiotherapy and immunotherapy combining with miRNA therapy.

Entities:  

Keywords:  chemotherapy; combined cancer therapy; immunotherapy; microRNA; radiotherapy

Mesh:

Substances:

Year:  2015        PMID: 25813091     DOI: 10.1517/14712598.2015.1030390

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  12 in total

Review 1.  Therapeutic nucleic acids: current clinical status.

Authors:  Kannan Sridharan; Nithya Jaideep Gogtay
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

Review 2.  Host miRNA and immune cell interactions: relevance in nano-therapeutics for human health.

Authors:  Yogesh Sharma; Adesh K Saini; Sheetal Kashyap; Gourav Chandan; Narinder Kaur; Vijai Kumar Gupta; Vijay Kumar Thakur; Vipin Saini; Reena V Saini
Journal:  Immunol Res       Date:  2021-10-29       Impact factor: 2.829

Review 3.  MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer.

Authors:  Jian Wang; Yong Du; Xiaoming Liu; William C Cho; Yinxue Yang
Journal:  Biomed Res Int       Date:  2015-05-06       Impact factor: 3.411

4.  miR-495 sensitizes MDR cancer cells to the combination of doxorubicin and taxol by inhibiting MDR1 expression.

Authors:  Zhenyou Zou; Ruyi Zou; Dan Zong; Yonghong Shi; Jinyao Chen; Jie Huang; Jiahui Zhu; Liguan Chen; Xiaoyan Bao; Yuan Liu; Weihao Liu; Wenhui Huang; Jingsang Hu; Zhi Chen; Xiaojie Lao; Chaoqun Chen; Xiaoli Huang; Yao Lu; Xueyin Ni; Daoquan Fang; Dengqiang Wu; Shuangshuang Lu; Mingzhu Jiang; Chenyang Qiu; Yuya Wu; Qisha Qiu; Yanyuan Dong; Yangyang Su; Chenmin Zhao; Zhihe Zhong; Jing Cai; Yong Liang
Journal:  J Cell Mol Med       Date:  2017-04-14       Impact factor: 5.310

5.  MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer.

Authors:  Lawrence W C Chan; Fengfeng Wang; Fei Meng; Lili Wang; Sze Chuen Cesar Wong; Joseph S K Au; Sijun Yang; William C S Cho
Journal:  Front Genet       Date:  2017-02-02       Impact factor: 4.599

Review 6.  MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours.

Authors:  Anna L Leichter; Michael J Sullivan; Michael R Eccles; Aniruddha Chatterjee
Journal:  Mol Cancer       Date:  2017-01-19       Impact factor: 27.401

Review 7.  The novel strategies for next-generation cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Garima Sharma; Bimal Kumar Sarkar; Sang-Soo Lee
Journal:  Oncotarget       Date:  2018-01-23

8.  miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.

Authors:  Margherita Gigante; Paola Pontrelli; Wolfgang Herr; Maddalena Gigante; Morena D'Avenia; Gianluigi Zaza; Elisabetta Cavalcanti; Matteo Accetturo; Giuseppe Lucarelli; Giuseppe Carrieri; Michele Battaglia; Walter J Storkus; Loreto Gesualdo; Elena Ranieri
Journal:  J Transl Med       Date:  2016-04-11       Impact factor: 5.531

Review 9.  Cancer and Aging - the Inflammatory Connection.

Authors:  Adar Zinger; William C Cho; Arie Ben-Yehuda
Journal:  Aging Dis       Date:  2017-10-01       Impact factor: 6.745

Review 10.  Targeting Epigenetic Aberrations in Pancreatic Cancer, a New Path to Improve Patient Outcomes?

Authors:  Brooke D Paradise; Whitney Barham; Martín E Fernandez-Zapico
Journal:  Cancers (Basel)       Date:  2018-04-28       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.